50 drugs reach their earliest generic-entry date in 2042

When

Applicant (as listed)

Basis

Jan 2042 · 4

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Xelstrym NDA 215401 · System · transdermal · 4 strengths dextroamphetamine	dextroamphetamine	Noven Pharms Inc	6 Jan 2042 patent	patent
Lasix Onyu NDA 217294 · Solution · subcutaneous furosemide	furosemide	Sq Innovation	10 Jan 2042 patent	patent
Galafold NDA 208623 · Capsule · oral migalastat hydrochloride	migalastat hydrochloride	Amicus Therap Us	11 Jan 2042 patent, carve-out possible	patent, carve-out possible
Rasonque NDA 220910 · Tablet · oral · 2 strengths daraxonrasib	daraxonrasib	Revolution Medicines	24 Jan 2042 patent	patent

Feb 2042 · 2

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Tyvaso NDA 022387 · Solution · inhalation treprostinil	treprostinil	United Therap	3 Feb 2042 patent, carve-out possible	patent, carve-out possible
Tyvaso Dpi NDA 214324 · Powder · inhalation · 5 strengths treprostinil	treprostinil	United Therap	3 Feb 2042 patent, carve-out possible	patent, carve-out possible

Mar 2042 · 4

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Sephience NDA 219666 · Powder · oral · 2 strengths sepiapterin	sepiapterin	Ptc Therap	6 Mar 2042 patent, carve-out possible	patent, carve-out possible
Ayvakit NDA 212608 · Tablet · oral · 3 strengths avapritinib	avapritinib	Blueprint Medicines	8 Mar 2042 patent, carve-out possible	patent, carve-out possible
Lumryz NDA 214755 · For suspension, extended release · oral · 4 strengths sodium oxybate	sodium oxybate	Alkermes Inc	16 Mar 2042 patent, carve-out possible	patent, carve-out possible
Uzedy NDA 213586 · Suspension, extended release · subcutaneous · 7 strengths risperidone	risperidone	Teva	17 Mar 2042 patent, carve-out possible	patent, carve-out possible

Apr 2042 · 4

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Vevye NDA 217469 · Solution · ophthalmic cyclosporine	cyclosporine	Harrow Eye	1 Apr 2042 patent	patent
Sezaby NDA 215910 · Powder · intravenous phenobarbital sodium	phenobarbital sodium	Sun Pharm Inds Inc	7 Apr 2042 patent	patent
Defencath NDA 214520 · Solution · n/a · 2 strengths heparin sodium; taurolidine	heparin sodium; taurolidine	Cormedix	15 Apr 2042 patent	patent
Axumin NDA 208054 · Solution · intravenous fluciclovine f-18	fluciclovine f-18	Blue Earth	23 Apr 2042 patent, carve-out possible	patent, carve-out possible

May 2042 · 6

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Xocova NDA 220442 · Tablet · oral ensitrelvir	ensitrelvir	Shionogi	1 May 2042 patent	patent
Ontralfy NDA 216190 · Solution · oral tizanidine hydrochloride	tizanidine hydrochloride	Fidelity Biopharma	7 May 2042 patent	patent
Flyrcado NDA 215168 · Solution · intravenous flurpiridaz f-18	flurpiridaz f-18	Ge Hlthcare	13 May 2042 patent	patent
Clotic NDA 217628 · Solution/drops · otic clotrimazole	clotrimazole	Carwin Pharm Assoc	26 May 2042 patent	patent
Otezla Xr NDA 210745 · Tablet, extended release · oral apremilast	apremilast	Amgen Inc	27 May 2042 patent	patent
Talicia NDA 213004 · Capsule, delayed release · oral amoxicillin; omeprazole magnesium; rifabutin	amoxicillin; omeprazole magnesium; rifabutin	Talicia Holdings	27 May 2042 patent, carve-out possible	patent, carve-out possible

Jun 2042 · 3

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Valtoco NDA 211635 · Spray · nasal · 3 strengths diazepam	diazepam	Neurelis Inc	10 Jun 2042 patent, carve-out possible	patent, carve-out possible
Nubeqa NDA 212099 · Tablet · oral darolutamide	darolutamide	Bayer Healthcare	17 Jun 2042 patent	patent
Welireg NDA 215383 · Tablet · oral belzutifan	belzutifan	Merck Sharp Dohme	30 Jun 2042 patent	patent

Jul 2042 · 7

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Gemtesa NDA 213006 · Tablet · oral vibegron	vibegron	Sumitomo Pharma Am	6 Jul 2042 patent, carve-out possible	patent, carve-out possible
Voxzogo NDA 214938 · Powder · subcutaneous · 3 strengths vosoritide	vosoritide	Biomarin Pharm	11 Jul 2042 patent, carve-out possible	patent, carve-out possible
Rezurock NDA 214783 · Tablet · oral belumosudil mesylate	belumosudil mesylate	Kadmon Pharms Llc	14 Jul 2042 patent, carve-out possible	patent, carve-out possible
Cardamyst NDA 218571 · Spray · nasal etripamil	etripamil	Milestone Pharms Usa	15 Jul 2042 patent, carve-out possible	patent, carve-out possible
Javadin NDA 220256 · Solution · oral clonidine hydrochloride	clonidine hydrochloride	Azurity	15 Jul 2042 patent	patent
Myqorzo NDA 219083 · Tablet · oral · 4 strengths aficamten	aficamten	Cytokinetics	15 Jul 2042 patent, carve-out possible	patent, carve-out possible
Vivimusta NDA 212209 · Solution · intravenous bendamustine hydrochloride	bendamustine hydrochloride	Azurity	29 Jul 2042 patent	patent

Aug 2042 · 2

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Opvee NDA 217470 · Spray · nasal nalmefene hydrochloride	nalmefene hydrochloride	Indivior	4 Aug 2042 patent, carve-out possible	patent, carve-out possible
Zoryve NDA 217242 · Foam · topical roflumilast	roflumilast	Arcutis	19 Aug 2042 patent	patent

Sep 2042 · 4

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Epidiolex NDA 210365 · Solution · oral cannabidiol	cannabidiol	Jazz Pharms Res	24 Sep 2042 patent, carve-out possible	patent, carve-out possible
Qulipta NDA 215206 · Tablet · oral atogepant	atogepant	Abbvie	27 Sep 2042 patent, carve-out possible	patent, carve-out possible
Jideytro NDA 220185 · Tablet · oral · 2 strengths zidesamtinib	zidesamtinib	Nuvalent	30 Sep 2042 patent	patent
Ztalmy NDA 215904 · Suspension · oral ganaxolone	ganaxolone	Immedica Pharma	30 Sep 2042 patent, carve-out possible	patent, carve-out possible

Oct 2042 · 1

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Qinlock NDA 213973 · Tablet · oral ripretinib	ripretinib	Deciphera Pharms	6 Oct 2042 patent, carve-out possible	patent, carve-out possible

Nov 2042 · 7

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Myfembree NDA 214846 · Tablet · oral estradiol; norethindrone acetate; relugolix	estradiol; norethindrone acetate; relugolix	Sumitomo Pharma Am	5 Nov 2042 patent	patent
Yuvezzi NDA 220142 · Solution/drops · ophthalmic brimonidine tartrate; carbachol	brimonidine tartrate; carbachol	Visus	10 Nov 2042 patent	patent
Yorvipath NDA 216490 · Solution · subcutaneous · 3 strengths palopegteriparatide	palopegteriparatide	Ascendis Pharma Bone	12 Nov 2042 patent	patent
Yuviwel NDA 219164 · Powder · subcutaneous · 3 strengths navepegritide	navepegritide	Ascendis	12 Nov 2042 patent	patent
Ibsrela NDA 211801 · Tablet · oral tenapanor hydrochloride	tenapanor hydrochloride	Ardelyx Inc	26 Nov 2042 patent	patent
Tagrisso NDA 208065 · Tablet · oral · 2 strengths osimertinib mesylate	osimertinib mesylate	Astrazeneca	26 Nov 2042 patent, carve-out possible	patent, carve-out possible
Xphozah NDA 213931 · Tablet · oral · 2 strengths tenapanor hydrochloride	tenapanor hydrochloride	Ardelyx Inc	26 Nov 2042 patent	patent

Dec 2042 · 6

Drug	Ingredient	Applicant	Earliest generic entry	Basis
Inqovi NDA 212576 · Tablet · oral cedazuridine; decitabine	cedazuridine; decitabine	Taiho Oncology	10 Dec 2042 patent, carve-out possible	patent, carve-out possible
Blujepa NDA 218230 · Tablet · oral gepotidacin mesylate	gepotidacin mesylate	Glaxosmithkline	13 Dec 2042 patent	patent
Tryptyr NDA 217370 · Solution/drops · ophthalmic acoltremon	acoltremon	Alcon Labs Inc	16 Dec 2042 patent	patent
Revuforj NDA 218944 · Tablet · oral · 3 strengths revumenib citrate	revumenib citrate	Syndax	18 Dec 2042 patent	patent
Avmapki Fakzynja Co-Pack (Copackaged) NDA 219616 · Capsule, tablet · oral avutometinib potassium; defactinib hydrochloride	avutometinib potassium; defactinib hydrochloride	Verastem Inc	29 Dec 2042 patent	patent
Sunosi NDA 211230 · Tablet · oral · 2 strengths solriamfetol hydrochloride	solriamfetol hydrochloride	Axsome Malta	30 Dec 2042 patent, carve-out possible	patent, carve-out possible